Product logins

Find logins to all Clarivate products below.


Pemphigus Vulgaris – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of pemphigus vulgaris comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed prevalence and the diagnosed incidence of pemphigus vulgaris for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s pemphigus vulgaris forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of pemphigus vulgaris and the number of new diagnoses of pemphigus vulgaris?
  • In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of pemphigus vulgaris and the number of new diagnoses of pemphigus vulgaris?
  • How will improvements in survival change the number of people living with a diagnosis of pemphigus vulgaris?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of pemphigus vulgaris over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following pemphigus vulgaris subpopulations:

  • Diagnosed incident cases
  • Diagnosed prevalent cases
  • Diagnosed incident cases by severity

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Ventolin HFA) and maintenance therapy to prevent…
Report
Renal Anemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Renal Anemia (US)
Renal anemia is a common complication of chronic kidney disease (CKD) resulting from insufficient erythropoietin production by impaired kidneys. The primary goal of renal anemia treatment is to…
Report
Atopic Dermatitis / Atopic Eczema – Current Treatment – Current Treatment: Physician Insights – Atopic Dermatitis / Atopic Eczema – Moderate to Severe (US)
AD is a chronic inflammatory skin condition characterized by recurrent flares and persistent itch, significantly impacting patient quality of life. Moderate to severe AD continues to undergo rapid…
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by autoantibodies at the neuromuscular junction. It leads to fluctuating muscle weakness and fatigue. Standard treatments include…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…